Journal of Hepatology
Volume 51, Issue 3 , Pages 548-556 , September 2009

Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

  • Yuichi Nozaki

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • ,
  • Koji Fujita

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • ,
  • Masato Yoneda

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • ,
  • Koichiro Wada

      Affiliations

    • Department of Pharmacology, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
    • ,
  • Yoshiyasu Shinohara

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • ,
  • Hirokazu Takahashi

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • ,
  • Hiroyuki Kirikoshi

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • ,
  • Masahiko Inamori

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • ,
  • Kensuke Kubota

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • ,
  • Satoru Saito

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • ,
  • Tetsuya Mizoue

      Affiliations

    • Department of Epidemiology and International Health, Research Institute, International Medical Center of Japan, Tokyo, Japan
    • ,
  • Naohiko Masaki

      Affiliations

    • Department of Gastroenterology, International Medical Center of Japan, Tokyo, Japan
    • ,
  • Yoji Nagashima

      Affiliations

    • Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
    • ,
  • Yasuo Terauchi

      Affiliations

    • Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan
    • ,
  • Atsushi Nakajima

      Affiliations

    • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 45 7872640; fax: +81 45 7878988.

Received 31 March 2009 ,Revised 30 April 2009 ,Accepted 8 May 2009.

References 

  1. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007;91:1125–1149
  2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;7:580–591
  3. Koh KK, Quon MJ. Combination therapy for treatment or prevention of atherosclerosis. Hypertension. 2008;52:e18
  4. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22:873–883
  5. Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann–Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–1204
  6. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann–Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA. 2005;102:8132–8137
  7. Zheng S, Hoos L, Cook J, Tetzloff G, Davis H, van Heek M, et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol. 2008;584:118–124
  8. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007;581:5664–5670
  9. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem. 2005;280:12710–12720
  10. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, et al. Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun. 2004;315:699–703
  11. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res. 2002;43:805–814
  12. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology. 2008;48:474–486
  13. Lam KS, Tiu SC, Tsang MW, Ip TP, Tam SC. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Diabetes Care. 1998;21:1154–1158
  14. Carrascosa JM, Molero JC, Fermı´n Y, Martı´nez C, Andrés A, Satrústegui J. Effects of chronic treatment with acarbose on glucose and lipid metabolism in obese diabetic Wistar rats. Diabetes Obes Metab. 2001;3:240–248
  15. Le Marchand-Brustel Y, Rochet N, Grémeaux T, Marot I, Van Obberghen E. Effect of an alpha-glycosidase inhibitor on experimentally-induced obesity in mice. Diabetologia. 1990;33:24–30
  16. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res. 1995;36:1073–1081
  17. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995;15:3012–3022
  18. Yeon JE, Choi KM, Baik SH, Kim KO, Lim HJ, Park KH, et al. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2004;19:799–804
  19. Horton JD. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans. 2002;30:1091–1095
  20. Sheng Z, Otani H, Brown MS, Goldstein JL. Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. Pro Natl Acad Sci USA. 1995;92:935–938
  21. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest. 1997;99:846–854
  22. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331–340
  23. Repa JJ, Turley SD, Quan G, Dietschy JM. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J Lipid Res. 2005;46:779–789

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding from industry or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00384-5

doi: 10.1016/j.jhep.2009.05.017

Journal of Hepatology
Volume 51, Issue 3 , Pages 548-556 , September 2009

Article Tools

* Image Usage & Resolution